litlas
Log inCreate account

David H. Vesole

Active 1990–2024

104
Papers
26,353
Citations
77
h-index
102
i10-index

Citations

Citations per year for David H. Vesole1948: 3 citations1989: 1 citations1990: 1 citations1991: 4 citations1992: 6 citations1993: 8 citations1994: 8 citations1995: 13 citations1996: 26 citations1997: 27 citations1998: 29 citations1999: 40 citations2000: 65 citations2001: 60 citations2002: 75 citations2003: 114 citations2004: 84 citations2005: 110 citations2006: 136 citations2007: 205 citations2008: 242 citations2009: 247 citations2010: 212 citations2011: 278 citations2012: 223 citations2013: 248 citations2014: 283 citations2015: 236 citations2016: 226 citations2017: 182 citations2018: 171 citations2019: 589 citations2020: 599 citations2021: 588 citations2022: 446 citations2023: 249 citations2024: 423 citations2025: 182 citations2026: 3 citations1949–1988: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,493 citing papers, 27.4% of this breakdownItaly: 557 citing papers, 6.1% of this breakdownFrance: 552 citing papers, 6.1% of this breakdownGermany: 532 citing papers, 5.8% of this breakdownUnited Kingdom: 502 citing papers, 5.5% of this breakdownSpain: 467 citing papers, 5.1% of this breakdownChina: 359 citing papers, 3.9% of this breakdownNetherlands: 341 citing papers, 3.8% of this breakdownCanada: 305 citing papers, 3.4% of this breakdownGreece: 278 citing papers, 3.1% of this breakdownAustralia: 240 citing papers, 2.6% of this breakdownBelgium: 224 citing papers, 2.5% of this breakdown
0%27.4%Other 24.7%

Institutions

Fields

  • Medicine82.6%
  • Immunology and Microbiology8.1%
  • Biochemistry, Genetics and Molecular Biology7.6%
  • Engineering0.4%
  • Mathematics0.2%
  • Neuroscience0.2%
  • Other0.9%

Topics

  • Multiple Myeloma Research and Treatments19.4%
  • Protein Degradation and Inhibitors7.9%
  • Peptidase Inhibition and Analysis4.2%
  • Cancer Treatment and Pharmacology3.6%
  • Hematopoietic Stem Cell Transplantation3.1%
  • CAR-T cell therapy research2.7%
  • Other59.1%

Coauthors

All papers

Open in search
  1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

    Authors: S. Vincent Rajkumar, Jean‐Luc Harousseau, Brian G.M. Durie, Kenneth C. Anderson, Meletios Α. Dimopoulos, Robert A. Kyle, Joan Bladé, Paul G. Richardson, Robert Z. Orlowski, David S. Siegel, Sundar Jagannath, Thierry Façon, Hervé Avet‐Loiseau, Sagar Lonial, Antonio Palumbo, Jeffrey A. Zonder, Heinz Ludwig, David H. Vesole, Orhan Sezer, Nikhil C. Munshi, Jesús F. San Miguel, on behalf of the International Myeloma Workshop Consensus Panel 1 - Blood 2011 cited by 1,034

  2. International uniform response criteria for multiple myeloma

    Authors: Brian G.M. Durie, J-L Harousseau, Jesús F. San Miguel, J Bladé, Bart Barlogie, Kenneth C. Anderson, Morie A. Gertz, Meletios Α. Dimopoulos, Jan Westin, Pieter Sonneveld, Heinz Ludwig, Gösta Gahrton, Meral Beksaç, John Crowley, Andrew Belch, M Boccadaro, Ingemar Turesson, D. Joshua, David H. Vesole, Robert A. Kyle, Raymond Alexanian, Guido Tricot, Michel Attal, Giampaolo Merlini, R Powles, Paul G. Richardson, Kazuyuki Shimizu, Patrizia Tosi, Gareth J. Morgan, S. Vincent Rajkumar, on behalf of the International Myeloma Working Group - Leukemia 2006 cited by 2,639

  3. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

    Authors: Robert A. Kyle, Brian G.M. Durie, S. Vincent Rajkumar, Ola Landgren, Joan Bladé, Giampaolo Merlini, Nicolaus Kröger, Hermann Einsele, David H. Vesole, Meletios Α. Dimopoulos, Jesús F. San Miguel, Hervé Avet‐Loiseau, Roman Hájek, W M Chen, Kenneth C. Anderson, Heinz Ludwig, Pieter Sonneveld, S Pavlovsky, Antonio Palumbo, Paul G. Richardson, Bart Barlogie, Patricia T. Greipp, Robert Vescio, Ingemar Turesson, Jan Westin, Mario Boccadoro, on behalf of the International Myeloma Working Group - Leukemia 2010 cited by 876

  4. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    Authors: Philippe Moreau, Shaji Kumar, Jesús F. San Miguel, Faith E. Davies, Elena Zamagni, Nizar J. Bahlis, Heinz Ludwig, Joseph Mıkhael, Evangelos Terpos, Fredrik Schjesvold, Thomas G. Martin, Kwee Yong, Brian G.M. Durie, Thierry Façon, Artur Jurczyszyn, Surbhi Sidana, Noopur Raje, Niels W.C.J. van de Donk, Sagar Lonial, Michèle Cavo, Sigurður Y. Kristinsson, Suzanne Lentzsch, Roman Hájek, Kenneth C. Anderson, Cristina João, Hermann Einsele, Pieter Sonneveld, Monika Engelhardt, Rafaël Fonseca, Annette Juul Vangsted, Katja Weisel, Rachid Baz, Vânia Hungria, Jesús G. Berdeja, Fernando Leal da Costa, Ângelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Bladé, Xavier Leleu, Eloísa Riva, P. Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf‐Henrik Mellqvist, Dominik Dytfeld, Jean‐Luc Harousseau, Hartmut Goldschmidt, Jacob P. Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksaç, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah A. Holstein, Orhan Sezer, Simon J. Harrison, Hareth Nahi, Gordon Cook, María‐Victoria Mateos, S. Vincent Rajkumar, Meletios Α. Dimopoulos, Paul G. Richardson - The Lancet Oncology 2021 cited by 268

  5. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

    Authors: Michèle Cavo, Evangelos Terpos, Cristina Nanni, Philippe Moreau, Suzanne Lentzsch, Sonja Zweegman, Jens Hillengaß, Monika Engelhardt, Saad Z. Usmani, David H. Vesole, Jesús F. San Miguel, Shaji Kumar, Paul G. Richardson, Joseph Mıkhael, Fernando Leal da Costa, Meletios Α. Dimopoulos, Chiara Zingaretti, Niels Abildgaard, Hartmut Goldschmidt, Robert Z. Orlowski, Wee Joo Chng, Hermann Einsele, Sagar Lonial, Bart Barlogie, Kenneth C. Anderson, S. Vincent Rajkumar, Brian G.M. Durie, Elena Zamagni - The Lancet Oncology 2017 cited by 520

  6. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline

    Authors: Joseph Mıkhael, Nofisat Ismaila, Matthew C. Cheung, Caitlin Costello, Madhav V. Dhodapkar, Shaji Kumar, Martha Q. Lacy, Brea Lipe, Richard F. Little, Anna S. Nikonova, James Omel, Namrata Peswani, Anca Prica, Noopur Raje, Rahul Seth, David H. Vesole, Irwin Walker, Alexander C. Whitley, Tanya M. Wildes, Sandy W. Wong, Tom Martin - Journal of Clinical Oncology 2019 cited by 333

  7. Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

    Authors: Laura Rosiñol, Meral Beksaç, Elena Zamagni, Niels W.C.J. van de Donk, Kenneth C. Anderson, Ashraf Badros, Jo Caers, Michèle Cavo, Meletios Α. Dimopoulos, Angela Dispenzieri, Hermann Einsele, Monika Engelhardt, Carlos Fernández de Larrea, Gösta Gahrton, Francesca Gay, Roman Hájek, Vânia Hungria, Artur Jurczyszyn, Nicolaus Kröger, Robert A. Kyle, Fernando Leal da Costa, Xavier Leleu, Suzanne Lentzsch, María‐Victoria Mateos, Giampaolo Merlini, Mohamad Mohty, Philippe Moreau, Leo Rasche, Donna Reece, Orhan Sezer, Pieter Sonneveld, Saad Z. Usmani, Karin Vanderkerken, David H. Vesole, Anders Waage, Sonja Zweegman, Paul G. Richardson, Joan Bladé - British Journal of Haematology 2021 cited by 174

  8. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.

    Authors: Ajay K. Nooka, Alexander M. Lesokhin, Mohamad Mohty, Rubén Niesvizky, Christopher Maisel, Bertrand Arnulf, Sarah Larson, Asya Varshavsky Yanovsky, Xavier Leleu, Lionel Karlin, David H. Vesole, Nizar J. Bahlis, Carlos Fernández de Larrea, Noopur Raje, Eric Leip, Umberto Conte, Mohamed Elmeliegy, Andrea Viqueira, Salomon Manier - Journal of Clinical Oncology 2023 cited by 42

  9. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Authors: Meletios Α. Dimopoulos, Pieter Sonneveld, Nelson Leung, Giampaolo Merlini, Heinz Ludwig, Efstathios Kastritis, Hartmut Goldschmidt, Douglas Joshua, Robert Z. Orlowski, Raymond Powles, David H. Vesole, Laurent Garderet, Hermann Einsele, Antonio Palumbo, Michèle Cavo, Paul G. Richardson, Philippe Moreau, Jesús F. San Miguel, S. Vincent Rajkumar, Brian G.M. Durie, Evangelos Terpos - Journal of Clinical Oncology 2016 cited by 419

  10. Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease

    Authors: Andrew J. Ullmann, Jeffrey H. Lipton, David H. Vesole, Pranatharthi Chandrasekar, Amelia Langston, Stefano Tarantolo, Hildegard Greinix, Wellington Morais de Azevedo, Vijay Reddy, Navdeep Boparai, Lisa D. Pedicone, Hernando Patino, Simon Durrant - New England Journal of Medicine 2007 cited by 1,336

  11. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

    Authors: S. Vincent Rajkumar, Susanna Jacobus, Natalie S. Callander, Rafaël Fonseca, David H. Vesole, Michael E. Williams, Rafat Abonour, David S. Siegel, Michael B. Katz, Philip R. Greipp - The Lancet Oncology 2009 cited by 933

  12. Bortezomib enhances dendritic cell (DC)–mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications

    Authors: Radek Špíšek, Anna Charalambous, Amitabha Mazumder, David H. Vesole, Sundar Jagannath, Madhav V. Dhodapkar - Blood 2007 cited by 378

  13. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

    Authors: Paul G. Richardson, David S. Siegel, Ravi Vij, Craig C. Hofmeister, Rachid Baz, Sundar Jagannath, Christine Chen, Sagar Lonial, Andrzej Jakubowiak, Nizar J. Bahlis, Kevin Song, Andrew Belch, Noopur Raje, Chaim Shustik, Suzanne Lentzsch, Martha Q. Lacy, Joseph Mıkhael, Jeffrey Matous, David H. Vesole, Min Chen, Mohamed H. Zaki, Christian Jacques, Zhinuan Yu, Kenneth C. Anderson - Blood 2014 cited by 384

  14. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

    Authors: Carlos Fernández de Larrea, Robert A. Kyle, Brian G.M. Durie, Heinz Ludwig, Saad Z. Usmani, David H. Vesole, Roman Hájek, Jesús F. San Miguel, Orhan Sezer, Pieter Sonneveld, Shaji Kumar, Anuj Mahindra, Raymond L. Comenzo, Antonio Palumbo, A Mazumber, Kenneth C. Anderson, Paul G. Richardson, Ashraf Badros, Jo Caers, Michèle Cavo, Xavier Leleu, Meletios Α. Dimopoulos, Chor Sang Chim, Rik Schots, A Noeul, Dorotea Fantl, U-H Mellqvist, Ola Landgren, Asher Chanan‐Khan, Philippe Moreau, Rafaël Fonseca, Giampaolo Merlini, Juan José Lahuerta, Joan Bladé, Robert Z. Orlowski, Jatin J. Shah, on behalf of the International Myeloma Working Group - Leukemia 2012 cited by 383

  15. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

    Authors: Edward A. Stadtmauer, Marcelo C. Pasquini, Beth Blackwell, Parameswaran Hari, Asad Bashey, Steven M. Devine, Yvonne A. Efebera, S. Ganguly, Cristina Gasparetto, Nancy L. Geller, Mary M. Horowitz, John Koreth, Kristin Knust, Heather Landau, Claudio G. Brunstein, Philip L. McCarthy, Courtney Nelson, Muzaffar H. Qazilbash, Nina Shah, David H. Vesole, Ravi Vij, Dan T. Vogl, Sergio Giralt, George Somlo, Amrita Krishnan - Journal of Clinical Oncology 2019 cited by 259

  16. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

    Authors: Antonio Palumbo, S. Vincent Rajkumar, Meletios Α. Dimopoulos, Paul G. Richardson, Jesús F. San Miguel, Bart Barlogie, Jean‐Luc Harousseau, Jeffrey A. Zonder, Michèle Cavo, Maurizio Zangari, Michel Attal, Andrew R. Belch, Stefan Knop, D. Joshua, Orhan Sezer, Heinz Ludwig, David H. Vesole, Joan Bladé, Robert A. Kyle, Jan Westin, Diane Weber, Sara Bringhen, Rubén Niesvizky, Anders Waage, Marie von Lilienfeld‐Toal, Sagar Lonial, Gareth J. Morgan, Robert Z. Orlowski, Kazuyuki Shimizu, Kenneth C. Anderson, Mario Boccadoro, Brian G.M. Durie, Pieter Sonneveld, M. A. Hussein, on behalf of the International Myeloma Working Group - Leukemia 2007 cited by 839

  17. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial

    Authors: Linda J. Burns, Daniel J. Weisdorf, Todd E. DeFor, David H. Vesole, T Repka, Bruce R. Blazar, Scott R. Burger, Angela Panoskaltsis‐Mortari, Carolyn A. Keever-Taylor, M-J Zhang, Jeffrey S. Miller - Bone Marrow Transplantation 2003 cited by 248

  18. Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)

    Authors: Angela Dispenzieri, Amrita Krishnan, Bonnie K. Arendt, Beth Blackwell, Paul K. Wallace, Surendra Dasari, Dan T. Vogl, Yvonne A. Efebera, Mingwei Fei, Nancy L. Geller, Sergio Giralt, Theresa Hahn, Alan Howard, Mindy Kohlhagen, Heather Landau, Parameswaran Hari, Marcelo C. Pasquini, Muzaffar H. Qazilbash, Philip L. McCarthy, Nina Shah, David H. Vesole, Edward A. Stadtmauer, David Murray - Blood Cancer Journal 2022 cited by 40

  19. Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).

    Authors: Parameswaran Hari, Marcelo C. Pasquini, Edward A. Stadtmauer, Raphael Fraser, Mingwei Fei, Steven M. Devine, Yvonne A. Efebera, Nancy L. Geller, Mary M. Horowitz, John Koreth, Heather Landau, Philip L. McCarthy, Muzaffar H. Qazilbash, Nina Shah, David H. Vesole, Dan T. Vogl, George Somlo, Amrita Krishnan, Sergio Giralt - Journal of Clinical Oncology 2020 cited by 102

  20. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

    Authors: Andrzej Jakubowiak, Dominik Dytfeld, Kent A. Griffith, Daniel Lebovic, David H. Vesole, Sundar Jagannath, Ammar Al-Zoubi, Tara Anderson, Brian K. Nordgren, Kristen Detweiler‐Short, Keith Stockerl‐Goldstein, Asra Ahmed, Terri L. Jobkar, Diane E. Durecki, Kathryn McDonnell, M. Mietzel, Daniel R. Couriel, Mark Kaminski, Ravi Vij - Blood 2012 cited by 434

  21. Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma

    Authors: Grzegorz Charliński, David H. Vesole, Artur Jurczyszyn - Cancers 2021 cited by 27

  22. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

    Authors: Shaji Kumar, Sergio Giralt, Edward A. Stadtmauer, Jean Luc Harousseau, Antonio Palumbo, William Bensinger, Raymond L. Comenzo, Suzanne Lentzsch, Nikhil C. Munshi, Rubén Niesvizky, Jesús F. San Miguel, Heinz Ludwig, Leif Bergsagel, Joan Bladé, Sagar Lonial, Kenneth C. Anderson, Patrizia Tosi, Pieter Sonneveld, Orhan Sezer, David H. Vesole, Michèle Cavo, Hermann Einsele, Paul G. Richardson, Brian G.M. Durie, S. Vincent Rajkumar - Blood 2009 cited by 233

  23. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report

    Authors: Jeffrey Schriber, Parameswaran Hari, Kwang Woo Ahn, Mingwei Fei, Luciano J. Costa, M A Kharfan-Dabaja, Miguel Angel-Diaz, Robert Peter Gale, Siddharatha Ganguly, Saulius Girnius, Shahrukh K. Hashmi, Attaphol Pawarode, David H. Vesole, Peter H. Wiernik, Baldeep Wirk, David I. Marks, Taiga Nishihori, Richard F. Olsson, Saad Z. Usmani, Tomer M. Mark, Yago Nieto, Anita D’Souza - Cancer 2017 cited by 87

  24. Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

    Authors: Brittany Knick Ragon, Mithun Vinod Shah, Anita D’Souza, Noel Estrada‐Merly, Lohith Gowda, Gemlyn George, Marcos de Lima, Shahrukh K. Hashmi, Mohamed A. Kharfan‐Dabaja, Navneet S. Majhail, Rahul Banerjee, Ayman Saad, Gerhard Hildebrandt, Hira Mian, Muhammad Bilal Abid, Minoo Battiwalla, Lazaros J. Lekakis, Sagar S. Patel, Hemant S. Murthy, Yago Nieto, Christopher Strouse, Sherif M. Badawy, Samer Al Hadidi, Bhagirathbhai Dholaria, Mahmoud Aljurf, David H. Vesole, Cindy H. Lee, Attaphol Pawarode, Usama Gergis, Kevin C. Miller, Leona Holmberg, Aimaz Afrough, Melhem Solh, Pashna N. Munshi, Taiga Nishihori, Larry D. Anderson, Baldeep Wirk, Gurbakhash Kaur, Muzaffar H. Qazilbash, Nina Shah, Shaji Kumar, Saad Z. Usmani - Blood Advances 2023 cited by 36